This week in drug discovery (18-22 September)  

News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer.

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

The top stories:

EU’s position as vaccines leader “at risk”, report reveals

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE).

UK scientists prepare for Nipah virus clinical trial

The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector.

Phase I trial of next-generation srRNA rabies vaccine

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies.

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as first-line therapy.

Partners to execute next generation Covid-19 vaccines clinical trial

ICON and the US Biomedical Advanced Research and Development Authority (BARDA) will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19 vaccine candidates.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free